Comprehensive suite of solutions designed to empower oncology care teams, accelerating patient diagnosis and treatment

Viz.ai’s strategic expansion into new oncology service line, enhances the company’s leadership in stroke care, cardiology, trauma, and radiology

SAN FRANCISCO: #ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz Oncology™ Suite, a transformative platform designed to accelerate access to life-saving cancer care. This marks a strategic expansion of Viz.ai’s proven capabilities into oncology, building on the company’s success in stroke, cardiology, respiratory, and radiology.

“Cancer remains one of the most urgent and complex clinical challenges in medicine today, Viz.ai is proud to bring our advanced AI platform to support oncology teams,” said Chris Mansi, MD, CEO and co-founder of Viz.ai. “This expansion aligns with our mission to increase access to lifesaving treatments. We bring our proven success in time-sensitive specialties to oncology, identifying patients faster, getting them to the right specialist sooner and streamlining clinical workflow. With the Viz Oncology Suite, we are enabling a similar transformation in cancer care – one that is patient-centered, data-driven, and scalable.”

Cancer care is inherently complex – requiring the integration of vast amounts of longitudinal data, cross-specialty collaboration, and timely, guideline-directed interventions. Despite this complexity, oncology care pathways remain fragmented and highly manual, often leading to delays and variability in care that can compromise patient outcomes—especially outside of major cancer centers where resources and specialist access may be more limited. The Viz Oncology Suite addresses this critical gap by delivering an end-to-end AI solution that streamlines coordination, surfaces high-risk patients earlier, and helps ensure that every patient has timely access to the care they need.

“Tools like the Viz Oncology Suite will bring AI-driven intelligence and automation to the front lines of oncology, enabling clinicians to identify and engage the right patients faster,” said Sara Nunnery, MD, MSCI, Director of Breast Cancer Research at Tennessee Oncology. “By streamlining complex oncology workflows and care team coordination, this technology has the potential to enhance care delivery and ultimately improve outcomes for our patients in the community.”

The oncology service line represents one of the largest and fastest-growing areas in healthcare, projected to nearly double in revenue over the next decade. Yet, clinical need far outweighs the capacity of current systems. The Viz Oncology Suite helps close this gap, giving providers the tools to deliver timely, guideline-directed care and empowering them to manage a growing volume of complex cases with greater efficiency and precision.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.

Fonte: Business Wire